FDA
-
-
-
-
-
-
-
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
-
-
-
-
-
-
-
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
-
-
-
-
-
-
-
GSK (GSK) Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
-
-
-
-
-
-
-
Baird Downgrades Agenus Inc. (AGEN) to Neutral
-
-
-
-
-
-
-
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
-
-
-
-
-
-
-
Agenus Inc. (AGEN) PT Lowered to $5 at B.Riley
-
-
-
-
-
-
-
Agenus Reports Second Quarter 2023 Results
-
333,970 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


